Press coverage about Baxter International (NYSE:BAX) has trended somewhat positive on Sunday, according to Accern. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Baxter International earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 45.8296572230311 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

A number of analysts have recently issued reports on the company. Cantor Fitzgerald set a $70.00 price objective on Baxter International and gave the company a “buy” rating in a research report on Wednesday, July 26th. Cowen and Company reaffirmed a “market perform” rating and issued a $68.00 price objective (up from $66.00) on shares of Baxter International in a research report on Thursday, July 27th. Citigroup Inc. assumed coverage on Baxter International in a research report on Thursday, August 17th. They issued a “neutral” rating and a $63.00 price objective for the company. Leerink Swann reaffirmed an “outperform” rating and issued a $75.00 price objective (up from $67.00) on shares of Baxter International in a research report on Thursday, July 27th. Finally, Zacks Investment Research cut Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Baxter International currently has a consensus rating of “Buy” and a consensus target price of $65.31.

Shares of Baxter International (NYSE:BAX) traded up 0.70% during trading on Friday, hitting $63.28. The stock had a trading volume of 2,582,962 shares. Baxter International has a 52 week low of $43.13 and a 52 week high of $64.40. The company’s 50 day moving average price is $61.16 and its 200 day moving average price is $57.19. The company has a market capitalization of $34.48 billion, a price-to-earnings ratio of 38.40 and a beta of 0.66.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Wednesday, July 26th. The medical instruments supplier reported $0.63 EPS for the quarter, beating the consensus estimate of $0.57 by $0.06. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The business had revenue of $2.61 billion for the quarter, compared to the consensus estimate of $2.59 billion. During the same quarter in the prior year, the business earned $0.46 earnings per share. Baxter International’s revenue for the quarter was up .8% on a year-over-year basis. Analysts predict that Baxter International will post $2.39 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 2nd. Investors of record on Friday, September 1st will be paid a $0.16 dividend. The ex-dividend date is Wednesday, August 30th. This represents a $0.64 annualized dividend and a yield of 1.01%. Baxter International’s payout ratio is 38.79%.

In related news, SVP Giuseppe Accogli sold 12,670 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $60.96, for a total value of $772,363.20. Following the transaction, the senior vice president now owns 33,286 shares in the company, valued at $2,029,114.56. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Carole J. Shapazian sold 4,020 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.61, for a total value of $247,672.20. Following the completion of the transaction, the director now owns 13,868 shares in the company, valued at approximately $854,407.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,050 shares of company stock worth $2,158,587. 0.05% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Baxter International (BAX) Earns Daily Coverage Optimism Score of 0.24” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/10/baxter-international-bax-earns-daily-coverage-optimism-score-of-0-24.html.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Stock Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related stocks with our FREE daily email newsletter.